The high-profile hedge fund run by veteran stockpicker Phil King has slashed the value of its stake in Opthea by two-thirds after the eye treatment biotech said it faced collapse after the failure of a key clinical trial.
While the company last traded at 60¢ per share, before it entered an extended pause ahead of the publication of the trial result, Regal Partners told investors it was now valuing Opthea at 20¢ per share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.